AbbVie is expanding an existing site in Puerto Rico at a cost of $30 million, adding to its capacity for biotechnology.

The proposed expansion will take place in AbbVie's site located in the northern municipality of Barceloneta, already home to two of the company's state-of-the-art facilities.

According to Stephen Muldoon, vice president of engineering and operations, the company is focused on "providing a significant impact on patients."

Puerto Rico Industrial Development Company (PRIDCO) is promoting the expansion with incentives for job creation and infrastructure.

"AbbVie's expansion in Barceloneta is very important for us, as this site is one of the world's most advanced biopharmaceutical facilities, contributing to our island's growing reputation as a biotech hub," said Puerto Rico governor Alejandro García Padilla.

The US drugmaker established its first manufacturing facility on the island in 1969. In addition to its commercial presence, the company has three manufacturing plants on the island. Together the three sites manufacture 13 products that support the therapeutic areas of immunology, virology and metabolic disorders.